<DOC>
	<DOC>NCT00130338</DOC>
	<brief_summary>The goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.</brief_summary>
	<brief_title>Rivastigmine Capsules in Patients With Probable Vascular Dementia</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia, Vascular</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Patients who complete the doubleblind treatment phase or those who have dropped out early in the study, but have returned for all the remaining scheduled efficacy assessments (retrieved dropout patients) without significant protocol violations are eligible to participate. Retrieved dropout patients, who have been treated with other cholinergic drugs during the past 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Vascular</keyword>
	<keyword>Rivastigmine</keyword>
	<keyword>Stroke</keyword>
	<keyword>Memory loss</keyword>
</DOC>